ZORYVE cream
Commercial- Indications
- Plaque psoriasis, Atopic dermatitis, Seborrheic dermatitis
Company intelligence / Profile preview
Bluefin
Westlake Village, California, United Statesarcutis.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Bluefin Therapeutics is a biotechnology company focused on developing novel small molecule therapeutics for inflammatory skin diseases. The company's primary focus is on the inhibition of the NF-kB signaling pathway, a key driver of inflammation in various dermatological conditions. In 2023, Bluefin was acquired by Arcutis Biotherapeutics, which integrated Bluefin's lead program, ARQ-255 (formerly a Bluefin asset), into its pipeline. This lead candidate is a topical small molecule designed to treat alopecia areata by targeting the underlying inflammatory mechanisms of the disease.
- Therapeutic areas
- Dermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Bluefin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bluefin.